Chromatin Regulator SPEN/SHARP in X Inactivation and Disease

• Main Authors: Benedetto Daniele Giaimo, Teresa Robert-Finestra, Franz Oswald, Joost Gribnau, Tilman Borggrefe
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Cancers
• Subjects: XCI; SHARP; Spen; NCoR; HDAC; polycomb
• Online Access: https://www.mdpi.com/2072-6694/13/7/1665

Enzymes, such as histone methyltransferases and demethylases, histone acetyltransferases and deacetylases, and DNA methyltransferases are known as epigenetic modifiers that are often implicated in tumorigenesis and disease. One of the best-studied chromatin-based mechanism is X chromosome inactivation (XCI), a process that establishes facultative heterochromatin on only one X chromosome in females and establishes the right dosage of gene expression. The specificity factor for this process is the long non-coding RNA <i>X</i> <i>inactive</i> <i>specific</i> <i>transcript</i> (<i>X</i><i>ist</i>), which is upregulated from one X chromosome in female cells. Subsequently, <i>X</i><i>ist</i> is bound by the corepressor SHARP/SPEN, recruiting and/or activating histone deacetylases (HDACs), leading to the loss of active chromatin marks such as H3K27ac. In addition, polycomb complexes PRC1 and PRC2 establish wide-spread accumulation of H3K27me3 and H2AK119ub1 chromatin marks. The lack of active marks and establishment of repressive marks set the stage for DNA methyltransferases (DNMTs) to stably silence the X chromosome. Here, we will review the recent advances in understanding the molecular mechanisms of how heterochromatin formation is established and put this into the context of carcinogenesis and disease.